BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lilienthal I, Herold N. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. Int J Mol Sci 2020;21:E6885. [PMID: 32961800 DOI: 10.3390/ijms21186885] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Huang X, Zhang W, Pu F, Zhang Z. LncRNA MEG3 promotes chemosensitivity of osteosarcoma by regulating antitumor immunity via miR-21-5p/p53 pathway and autophagy. Genes & Diseases 2021. [DOI: 10.1016/j.gendis.2021.11.004] [Reference Citation Analysis]
2 Pang H, Wu T, Peng Z, Tan Q, Peng X, Zhan Z, Song L, Wei B. Baicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and β-catenin signaling pathways. Journal of Bone Oncology 2022;33:100415. [DOI: 10.1016/j.jbo.2022.100415] [Reference Citation Analysis]
3 Li J, Wu Z, Wang J, Wu T, Shen Z, Zhang L, Lv J, Bai J, Feng Y. Necdin, one of the important pathway proteins in the regulation of osteosarcoma progression by microRNA-200c. Bioengineered 2022;13:8915-25. [PMID: 35333696 DOI: 10.1080/21655979.2022.2056693] [Reference Citation Analysis]
4 Ma XL, Zhan TC, Hu JP, Zhang CL, Zhu KP. Doxorubicin-induced novel circRNA_0004674 facilitates osteosarcoma progression and chemoresistance by upregulating MCL1 through miR-142-5p. Cell Death Discov 2021;7:309. [PMID: 34689155 DOI: 10.1038/s41420-021-00694-8] [Reference Citation Analysis]
5 Xue Y, Guo Y, Liu N, Deng Z, Jian Y, Cai H, Meng X. MicroRNA-22-3p targeted regulating transcription factor 7-like 2 (TCF7L2) constrains the Wnt/β-catenin pathway and malignant behavior in osteosarcoma. Bioengineered 2021. [PMID: 34753394 DOI: 10.1080/21655979.2021.2003942] [Reference Citation Analysis]
6 Liang C, Yu X, Xiong N, Zhang Z, Sun Z, Dong Y. Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway. Front Oncol 2020;10:615146. [PMID: 33659212 DOI: 10.3389/fonc.2020.615146] [Reference Citation Analysis]
7 Xu Y, Li Y, Chen X, Xiang F, Deng Y, Li Z, Wei D. TGF-β protects osteosarcoma cells from chemotherapeutic cytotoxicity in a SDH/HIF1α dependent manner. BMC Cancer 2021;21:1200. [PMID: 34763667 DOI: 10.1186/s12885-021-08954-7] [Reference Citation Analysis]
8 Luo Y, Lv B, He S, Zou K, Hu K. Identification of Gene as Predictive Biomarkers for the Occurrence and Recurrence of Osteosarcoma. Int J Gen Med 2021;14:1773-83. [PMID: 33994806 DOI: 10.2147/IJGM.S312277] [Reference Citation Analysis]
9 Zhang J, Ding R, Wu T, Jia J, Cheng X. Autophagy-Related Genes and Long Noncoding RNAs Signatures as Predictive Biomarkers for Osteosarcoma Survival. Front Cell Dev Biol 2021;9:705291. [PMID: 34513835 DOI: 10.3389/fcell.2021.705291] [Reference Citation Analysis]
10 Lou J, Zhang H, Xu J, Ren T, Huang Y, Tang X, Guo W. circUSP34 accelerates osteosarcoma malignant progression by sponging miR-16-5p. Cancer Sci 2021. [PMID: 34592064 DOI: 10.1111/cas.15147] [Reference Citation Analysis]
11 Santos A, Domingues C, Jarak I, Veiga F, Figueiras A. Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach. Eur J Pharm Biopharm 2021:S0939-6411(21)00352-0. [PMID: 34896571 DOI: 10.1016/j.ejpb.2021.12.003] [Reference Citation Analysis]
12 Yu S, Guo L, Yan B, Yuan Q, Shan L, Zhou L, Efferth T. Tanshinol suppresses osteosarcoma by specifically inducing apoptosis of U2-OS cells through p53-mediated mechanism. J Ethnopharmacol 2022;292:115214. [PMID: 35331874 DOI: 10.1016/j.jep.2022.115214] [Reference Citation Analysis]
13 Landuzzi L, Manara MC, Lollini PL, Scotlandi K. Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma. Cells 2021;10:416. [PMID: 33671173 DOI: 10.3390/cells10020416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Chen X, Liu L, Liu P, Chen Y, Lin D, Yan H, Yan Q, Wang Y, Qiu Y, Fang B, Huang H, Qian J, Zhao Y, Du Z, Zhang Q, Li X, Zheng X, Liu Z. Discovery of Potent and Orally Bioavailable Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for the Treatment of Osteosarcoma. J Med Chem 2022. [PMID: 35239349 DOI: 10.1021/acs.jmedchem.1c01732] [Reference Citation Analysis]
15 Li S, Liu F, Zheng K, Wang W, Qiu E, Pei Y, Wang S, Zhang J, Zhang X. CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis. Mol Cancer 2021;20:161. [PMID: 34876132 DOI: 10.1186/s12943-021-01453-0] [Reference Citation Analysis]
16 Giannikopoulos P, Parham DM. Pediatric Sarcomas: The Next Generation of Molecular Studies. Cancers 2022;14:2515. [DOI: 10.3390/cancers14102515] [Reference Citation Analysis]
17 Sanapour N, Malakoti F, Shanebandi D, Targhazeh N, Yousefi B, Soleimanpour J, Majidinia M. Thymoquinone Augments Methotrexate-Induced Apoptosis on Osteosarcoma Cells. Drug Res (Stuttg) 2022;72:220-5. [PMID: 35385883 DOI: 10.1055/a-1775-7908] [Reference Citation Analysis]
18 Ren Z, Hu Y, Sun J, Kang Y, Li G, Zhao H. N6-methyladenosine methyltransferase WTAP-stabilized FOXD2-AS1 promotes the osteosarcoma progression through m6A/FOXM1 axis. Bioengineered 2022;13:7963-73. [PMID: 35356854 DOI: 10.1080/21655979.2021.2008218] [Reference Citation Analysis]
19 He Q, Yu C, Li Y, Hao P, Mai H, Guo R, Zhong G, Zhang K, Wong C, Chen Q, Chen Y. ERRα contributes to HDAC6-induced chemoresistance of osteosarcoma cells. Cell Biol Toxicol 2021. [PMID: 34524571 DOI: 10.1007/s10565-021-09651-8] [Reference Citation Analysis]
20 Mikulčić M, Tabrizi-Wizsy NG, Bernhart EM, Asslaber M, Trummer C, Windischhofer W, Sattler W, Malle E, Hrzenjak A. 15d-PGJ2 Promotes ROS-Dependent Activation of MAPK-Induced Early Apoptosis in Osteosarcoma Cell In Vitro and in an Ex Ovo CAM Assay. Int J Mol Sci 2021;22:11760. [PMID: 34769194 DOI: 10.3390/ijms222111760] [Reference Citation Analysis]
21 Bian X, Guo T, Zhang J, Xia J, Feng X, Wang F, Lin M, Tian W, Villarreal-gómez LJ. The Magnetic Nanomaterial Biofunctions in Cancer Diagnosis and Therapy. Journal of Nanomaterials 2021;2021:1-9. [DOI: 10.1155/2021/9968166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Xie C, Xiang W, Shen H, Shen J. GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma. J Orthop Surg Res 2021;16:713. [PMID: 34876170 DOI: 10.1186/s13018-021-02859-8] [Reference Citation Analysis]
23 Marchandet L, Lallier M, Charrier C, Baud'huin M, Ory B, Lamoureux F. Mechanisms of Resistance to Conventional Therapies for Osteosarcoma. Cancers (Basel) 2021;13:683. [PMID: 33567616 DOI: 10.3390/cancers13040683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
24 Wang S, Lin B, Liu W, Wei G, Li Z, Yu N, Xue X, Ji G. Acacetin Induces Apoptosis in Human Osteosarcoma Cells by Modulation of ROS/JNK Activation. Drug Des Devel Ther 2020;14:5077-85. [PMID: 33239866 DOI: 10.2147/DDDT.S275148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
25 Hattinger CM, Patrizio MP, Fantoni L, Casotti C, Riganti C, Serra M. Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. Cancers (Basel) 2021;13:2878. [PMID: 34207685 DOI: 10.3390/cancers13122878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Da W, Tao L, Zhu Y. The inhibitory effect of CTAB on human osteosarcoma through the PI3K/AKT signaling pathway. Int J Oncol 2021;59:42. [PMID: 34013357 DOI: 10.3892/ijo.2021.5222] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Serra M, Hattinger CM, Pasello M, Casotti C, Fantoni L, Riganti C, Manara MC. Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not? Cells 2021;10:2461. [PMID: 34572110 DOI: 10.3390/cells10092461] [Reference Citation Analysis]
28 Song X, Zhang H, Yin F, Guo P, Yang X, Liu J, Han Y, Ren Z. Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis. Mediators Inflamm 2021;2021:3456629. [PMID: 34720749 DOI: 10.1155/2021/3456629] [Reference Citation Analysis]
29 Gazouli I, Kyriazoglou A, Kotsantis I, Anastasiou M, Pantazopoulos A, Prevezanou M, Chatzidakis I, Kavourakis G, Economopoulou P, Kontogeorgakos V, Papagelopoulos P, Psyrri A. Systematic Review of Recurrent Osteosarcoma Systemic Therapy. Cancers (Basel) 2021;13:1757. [PMID: 33917001 DOI: 10.3390/cancers13081757] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
30 Zhong S, Zhang Z, Guo Z, Yang W, Dou G, Lv X, Wang X, Ge J, Wu B, Pan X, Wang H, Mou Y. Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study. Bioengineered 2022;13:12003-20. [DOI: 10.1080/21655979.2021.2011631] [Reference Citation Analysis]
31 Truong D, Cherradi-lamhamedi S, Ludwig JA. Targeting the IGF/PI3K/mTOR Pathway and AXL/YAP1/TAZ pathways in Primary Bone Cancer. Journal of Bone Oncology 2022. [DOI: 10.1016/j.jbo.2022.100419] [Reference Citation Analysis]
32 Huang Z, Huang L, Liu L, Wang L, Lin W, Zhu X, Su W, Lv C. Knockdown of microRNA-203 reduces cisplatin chemo-sensitivity to osteosarcoma cell lines MG63 and U2OS in vitro by targeting RUNX2. J Chemother 2021;33:328-41. [PMID: 33764270 DOI: 10.1080/1120009X.2021.1899441] [Reference Citation Analysis]
33 Sterz U, Grube M, Herr W, Menhart K, Wendl C, Vogelhuber M. Case Report: Dual Checkpoint Inhibition in Advanced Metastatic Osteosarcoma Results in Remission of All Tumor Manifestations-A Report of a Stunning Success in a 37-Year-Old Patient. Front Oncol 2021;11:684733. [PMID: 34422638 DOI: 10.3389/fonc.2021.684733] [Reference Citation Analysis]
34 Gao P, Zhao X, Yu K, Zhu Z. Circ_0084582 Facilitates Cell Growth, Migration, Invasion, and Angiopoiesis in Osteosarcoma via Mediating the miR-485-3p/JAG1 Axis. Front Genet 2021;12:690956. [PMID: 34421997 DOI: 10.3389/fgene.2021.690956] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Yang S, Xiao H, Sun Y, Cao L. Zeylenone synergizes with cisplatin in osteosarcoma by enhancing DNA damage, apoptosis, and necrosis via the Hsp90/AKT/GSK3β and Fanconi anaemia pathway. Phytother Res 2021;35:5899-918. [PMID: 34585447 DOI: 10.1002/ptr.7299] [Reference Citation Analysis]
36 Mancarella C, Morrione A, Scotlandi K. Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options. Cells 2021;10:2075. [PMID: 34440844 DOI: 10.3390/cells10082075] [Reference Citation Analysis]
37 Cao D, Ge S, Li M. MiR-451a Promotes Cell Growth, Migration and EMT in Osteosarcoma by Regulating YTHDC1-mediated m6A Methylation to Activate the AKT/mTOR Signaling Pathway. Journal of Bone Oncology 2022. [DOI: 10.1016/j.jbo.2022.100412] [Reference Citation Analysis]